US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

18.19

-0.5900-3.14%

Volume:638.23K

Turnover:11.70M

Market Cap:2.38B

PE:15.31

High:18.74

Open:18.62

Low:18.17

Close:18.78

Loading ...

Overview Company News Filings

Jazz Pharmaceuticals reports 15.2 months median PFS in Phase 2 trial

Argenx selloff misses growth potential for PFS format, says Wedbush

AstraZeneca says Enhertu combo showed PFS improvement over THP in trial

Summit Therapeutics: Buy Rating Backed by Promising Ivonescimab Trial and Favorable PFS Outcomes

Press Release: BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

Accent Resources Initiates Pre-Feasibility Study for Magnetite Range Project

Press Release: Theriva(TM) Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Press Release: IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

Press Release: Immatics Announces First Quarter 2025 Financial Results and Business Update

Press Release: ArriVent BioPharma Reports First Quarter 2025 Financial Results

Press Release: IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation

Top US Uranium Mine Reports Record Monthly Production and Exceptional Drill Results to Support Domestic Nuclear Energy Production

Press Release: Lithium Royalty Corp. Announces First Quarter 2025 Results

BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":18.19,"timestamp":1752609600000,"preClose":18.78,"halted":0,"volume":638229,"delay":0,"floatShares":126185309,"shares":130659942,"eps":1.188092,"marketStatus":"Pre-Mkt","change":-0.59,"latestTime":"07-16 06:47:47 EDT","open":18.62,"high":18.74,"low":18.17,"amount":11704724.158019999,"amplitude":0.030351,"askPrice":22.79,"askSize":100,"bidPrice":16.01,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.188092,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1752672600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":18.19,"dividendRate":0.052776,"postHourTrading":{"tag":"盘后","latestPrice":18.19,"preClose":18.19,"latestTime":"17:30 EDT","volume":78760,"amount":1432644.8,"timestamp":1752615058328},"volumeRatio":1.218567793986759,"impliedVol":0.5016,"impliedVolPercentile":0.9639},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126185309,"roa":"0.77%","roe":"6.77%","lyrEps":1.053397,"volumeRatio":1.218567793986759,"shares":130659942,"dividePrice":0.96,"high":18.74,"amplitude":0.030351,"preClose":18.78,"low":18.17,"week52Low":14.335,"pbRate":"0.89","psRate":"3.39","week52High":22.24,"institutionHeld":0.6776,"latestPrice":18.19,"eps":1.188092,"divideRate":0.052776,"volume":638229,"delay":0,"ttmEps":1.188092,"open":18.62,"prevYearClose":18.87,"prevWeekClose":18.54,"prevMonthClose":17.53,"prevQuarterClose":17.53,"fiveDayClose":18.73,"twentyDayClose":16.43,"sixtyDayClose":15.24,"earningDate":1753286400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540920427","title":"Jazz Pharmaceuticals reports 15.2 months median PFS in Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540920427","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540920427?lang=en_us&edition=fundamental","pubTime":"2025-06-03 00:55","pubTimestamp":1748883306,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals (JAZZ) announced long-term data, including the first report of median overall survival from the Phase 2 trial evaluating Ziihe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jazz-pharmaceuticals-reports-15-2-months-median-pfs-in-phase-2-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jazz-pharmaceuticals-reports-15-2-months-median-pfs-in-phase-2-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0823416689.USD","BK4195","IE00BN0W2T93.GBP","BK4533","IE00BN0W2V16.EUR","LU0889565916.HKD","BK4211","LU0320765992.SGD","JAZZ","PFS","BK4532","IE00BN0W2W23.USD","BK4007"],"gpt_icon":0},{"id":"2540879152","title":"Argenx selloff misses growth potential for PFS format, says Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2540879152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540879152?lang=en_us&edition=fundamental","pubTime":"2025-06-02 22:55","pubTimestamp":1748876111,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten says investors reacted negatively to Argenx’s (ARGX) Q1 earnings, but the current share price undervalues the op...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/argenx-selloff-misses-growth-potential-for-pfs-format-says-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/argenx-selloff-misses-growth-potential-for-pfs-format-says-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARGX","BK4139","LU0320765992.SGD","PFS","BK4588","BK4211","BK4505","BK4195","LU0109394709.USD","LU0889565916.HKD","BK4585"],"gpt_icon":0},{"id":"2540986337","title":"AstraZeneca says Enhertu combo showed PFS improvement over THP in trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2540986337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540986337?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:16","pubTimestamp":1748866564,"startTime":"0","endTime":"0","summary":"Results from the DESTINY-Breast09 Phase III trial showed Enhertu plus pertuzumab demonstrated a highly statistically significant and clinically mea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-says-enhertu-combo-showed-pfs-improvement-over-thp-in-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-says-enhertu-combo-showed-pfs-improvement-over-thp-in-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PFS","BK4211","BK4195"],"gpt_icon":0},{"id":"2539422800","title":"Summit Therapeutics: Buy Rating Backed by Promising Ivonescimab Trial and Favorable PFS Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2539422800","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539422800?lang=en_us&edition=fundamental","pubTime":"2025-05-30 17:58","pubTimestamp":1748599094,"startTime":"0","endTime":"0","summary":"Mohit Bansal, an analyst from Wells Fargo, maintained the Buy rating on Summit Therapeutics (SMMT – Research Report). The associated price target i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/summit-therapeutics-buy-rating-backed-by-promising-ivonescimab-trial-and-favorable-pfs-outcomes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/summit-therapeutics-buy-rating-backed-by-promising-ivonescimab-trial-and-favorable-pfs-outcomes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PFS","LENZ","SMMF"],"gpt_icon":0},{"id":"2538468287","title":"Press Release: BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2538468287","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538468287?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:00","pubTimestamp":1748343600,"startTime":"0","endTime":"0","summary":"- New data from pilot phase of ongoing CheMo4METPANC Phase 2b combination trial of motixafortide in PDAC, sponsored by Columbia University, to be presented at upcoming 2025 ASCO Annual Meeting --. - APHEXDA performing well under Ayrmid stewardship -. - Management to host conference call today, May 27 , at 8:30 am EDT -. TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update.\"Following our announcement last November that we out-licensed APHEXDA, our FDA-approved stem cell mobilization agent, to Ayrmid Ltd., we have been actively evaluating new assets in the areas of oncology and rare disease where we can leverage our drug development and regulatory expertise to bring new medicines to market,\" said Philip Serlin, Chief Executive Officer of BioLineRx. \"I r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BLRX","BK4139","BK4022","R","SCD","BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2537673648","title":"Accent Resources Initiates Pre-Feasibility Study for Magnetite Range Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2537673648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537673648?lang=en_us&edition=fundamental","pubTime":"2025-05-21 09:28","pubTimestamp":1747790896,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Accent Resources NL ( ($AU:ACS) ). Accent Resources NL has initiated a Pre-Feasibility Study (PFS) for its Magn...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/accent-resources-initiates-pre-feasibility-study-for-magnetite-range-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/accent-resources-initiates-pre-feasibility-study-for-magnetite-range-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2535021536","title":"Press Release: Theriva(TM) Biologics Reports First Quarter 2025 Operational Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535021536","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535021536?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:40","pubTimestamp":1747226400,"startTime":"0","endTime":"0","summary":"- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial -. - Closed a public offering on May 8, 2025, raising the Company's cash balance and extending its cash runway into the first quarter of 2026 -. ROCKVILLE, Md., May 14, 2025  -- Theriva Biologics , a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.\"We have started 2025 with outstanding clinical progress,\" said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. \"The VIRAGE Phase 2b clinical trial of VCN-01  with gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients achieved its primary survival and safety endpoints, highlighting the potential therapeutic benefits of our oncolytic virus platform. We are working to scale up ma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","TOVX","BK4211","BK4099","OS","TM","03160","BK4195","BK4588","BK4555","BK4604","BK4097","BK4139","PFS"],"gpt_icon":0},{"id":"2535268110","title":"Press Release: IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2535268110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535268110?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:05","pubTimestamp":1747224300,"startTime":"0","endTime":"0","summary":"-- Primary endpoint of pivotal Phase 3 trial  of lead. investigational therapeutic cancer vaccine in patients with advanced. melanoma still expected to readout in third quarter of 2025. -- Data presented at recent congresses reinforces the potential of the. company's T-Win candidates to reshape the tumor microenvironment and. -- Company recognized as one of the most innovative biotechnology companies. \"IO Biotech continues to make meaningful progress developing novel cancer therapies that are designed to address significant unmet needs in melanoma and other hard-to-treat cancers, and we are thrilled to be recognized for our work by Fast Company as one of the most innovative companies in the world,\" said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. \"This year, we remain focused on delivering our Phase 3 data, preparing a Biologics License Application  and planning for commercialization of Cylembio , our potentially first-in-class, immune-modulatory, off-the-shelf therapeutic c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0203347892.USD","LU1291159041.SGD","BK4535","LU0965508806.USD","LU1162221912.USD","LU1037948541.HKD","IE00BJT1NW94.SGD","LU2361044949.HKD","LU0106261372.USD","BK4509","BK4559","BK4195","PFS","LU0985320562.USD","LU2112291526.USD","LU2324357040.USD","BK4022","LU1116320737.USD","IOBT","LU0211331839.USD","LU0320765646.SGD","LU0359202008.SGD","LU2361044865.SGD","LU1093756168.USD","LU2461242641.AUD","BK4548","IE00BYTNYN87.SGD","LU0965509010.AUD","TME","IE0009355771.USD","LU1917777945.USD","SG9999014542.SGD","LU1066051225.USD","LU0965509101.SGD","BK4211","SG9999001176.SGD","BK4139","BK4550","IE00BSNM7G36.USD","LU1430594728.SGD","LU1974910355.USD","LU2106854487.HKD","SG9999015358.SGD","R","01698","LU0070302665.USD","BK4588","LU0861579265.USD"],"gpt_icon":1},{"id":"2535025235","title":"Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025235","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025235?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:00","pubTimestamp":1747224000,"startTime":"0","endTime":"0","summary":"LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress  and the 18 International Conference on Malignant Lymphoma ; ZYNLONTA plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability. Cash runway expected to fund multiple catalysts into the second half of 2026. LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.\"We are encouraged by the promising LOTIS-7 abstract data, which we believe demonstrate the potential for ZYNLONTA plus glofitamab to be a best-in-class combination in a dynamic market,\" said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. \"Coupled with the progress of our LOTIS-5 confirmatory trial, we are confident in our path forward and the potential of ZYNLON","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4080","BK4139","BK4007","PBD","ORR","BK4505","LENZ","BK4232","BK4195","PFS","BK4231","BK4022","BK4539","BK4211","CR","ADCT","R","ADC"],"gpt_icon":0},{"id":"2535726182","title":"Press Release: Immatics Announces First Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535726182","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535726182?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:00","pubTimestamp":1747134000,"startTime":"0","endTime":"0","summary":"-- IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME,in previously treated advanced melanoma ongoing and expected to complete. data in metastatic melanoma with substantially longer follow-up and. additional uveal melanoma patients to be presented in an oral. -- IMA203CD8 PRAME Cell Therapy : Phase 1a clinical trial in solid. -- IMA402 PRAME Bispecific: Phase 1a clinical trial in solid tumors ongoing. -- Combination of IMA203 PRAME cell therapy and Moderna's PRAME adaptive. -- IMA401 MAGEA4/8 Bispecific: Phase 1a clinical trial, including a. IMA203 is Immatics' lead PRAME cell therapy, currently being evaluated in a Phase 3 trial  in patients with previously treated advanced melanoma. IMA203 has the potent","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","IMTX","BK4211","BK4195","ORR","BK4139","PFS","BK4097"],"gpt_icon":0},{"id":"2534722462","title":"Press Release: ArriVent BioPharma Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534722462","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534722462?lang=en_us&edition=fundamental","pubTime":"2025-05-12 20:00","pubTimestamp":1747051200,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in global pivotal Phase 3 study for firmonertinib. monotherapy in first-line NSCLC harboring EGFR exon 20 insertion. -- Planned update for development of firmonertinib in first-line NSCLC PACC. -- First IND for ARR-217 , an antibody drug conjugate . -- Cash, cash equivalents and marketable securities of $205.5 million as of. \"We continued our strong execution across our oncology-focused pipeline and are preparing for several near-term milestones. Importantly, our late-stage firmonertinib program continues to show differentiated potential to address unmet needs across EGFR-mutant non-small cell lung cancer ,\" said Bing Yao, Chairman and Chief Executive Officer of ArriVent. \"ARR-217 , our recently acquired antibody drug conjugate  targeting the gastrointestinal marker CDH17 with best-in-class potential, is expected to be the first ADC from our pipeline to enter the clinic.\". -- Completed enrollment for pivotal trial. During the first quarter of 2025,we completed e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4139","BK4211","BK4231","PFS","AVBP","BK4080","PACC","BK4195"],"gpt_icon":0},{"id":"2533896514","title":"Press Release: IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2533896514","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533896514?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:00","pubTimestamp":1746648000,"startTime":"0","endTime":"0","summary":"-- Phase 1 clinical data of INB-100 continues to demonstrate long-term. durable remissions, with 100% of treated Acute Myeloid Leukemia . patients remaining relapse-free with median follow-up of 20.1 months as. of January 17, 2025, as presented at the 2025 Transplantation & Cellular. -- On May 1st, 2025, we celebrated the 5th anniversary of the first patient. ever treated with a gamma-delta T cell therapy being developed by IN8bio.This older patient with complex AML and multiple genetic abnormalities. was treated with INB-100 and remains alive and in remission today. NEW YORK, May 07, 2025  -- IN8bio, Inc. , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the first quarter ended March 31, 2025 and recent corporate highlights.Expanded Pipeline with INB-600 Gamma-Delta T Cell Engager Platform","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","INAB","BK4099","BK4588","IE00B7SZL793.SGD","SBC","LU2065731478.USD","CRS","OS","BK4139","PFS","BK4539","BK4196","BK4585","BK4555","BK4211","BK4006","03160","TM","BK4604","BK4097","IE00B66KJ199.SGD","BK4195","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2533950493","title":"Press Release: IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533950493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533950493?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:05","pubTimestamp":1746525900,"startTime":"0","endTime":"0","summary":"-- $1.05 billion of cash, cash equivalents and marketable securities as of. March 31, 2025, and an updated cash runway guidance into 2029; commercial. -- Over 300 patients enrolled in darovasertib and crizotinib registrational. 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to. -- Successful FDA Type D meeting completed to finalize darovasertib Ph3. registrational trial design and received U.S. FDA Breakthrough Therapy. -- Targeting three darovasertib program clinical data updates at medical. conferences in 2025, including 1L MUM mOS results in >40 patients and. targeting clinical data update in over 40 SCLC patients at a medical. SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter that ended March 31, 2025.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4022","BK4231","PB","R","PFS","BK4139","BK4232","BK4195","BK4211","BK4080","IDYA","OS","BK4097"],"gpt_icon":0},{"id":"2533885504","title":"Buy Rating for Janux Therapeutics Inc: Promising PFS Data and Attractive Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2533885504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533885504?lang=en_us&edition=fundamental","pubTime":"2025-05-06 17:58","pubTimestamp":1746525518,"startTime":"0","endTime":"0","summary":"Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Janux Therapeutics Inc (JANX – Research Report). The assoc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-janux-therapeutics-inc-promising-pfs-data-and-attractive-valuation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-janux-therapeutics-inc-promising-pfs-data-and-attractive-valuation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JANX","LENZ","PFS"],"gpt_icon":0},{"id":"2532318075","title":"Top US Uranium Mine Reports Record Monthly Production and Exceptional Drill Results to Support Domestic Nuclear Energy Production","url":"https://stock-news.laohu8.com/highlight/detail?id=2532318075","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532318075?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"Energy Fuels' Pinyon Plain Mine in Arizona produces a record 151,400 pounds of U3O8 contained in ore for the month of April; Underground drill program identifies large areas of uranium mineralization with average grades believed to be unprecedented in the modern era of U.S. uranium mining.DENVER, May 1, 2025 /PRNewswire/ -Energy Fuels Inc.  , a leading U.S. producer of uranium, rare earth elements , and other critical minerals today reported that uranium mining rates at its Pinyon Plain mine in Arizona reached record levels in April, while the ongoing underground drill program at the mine delivers exceptional new results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/top-us-uranium-mine-reports-110000156.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-us-uranium-mine-reports-110000156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NA","BK4156","BK4141","PFS","UEC","BK4606","UUUU","REE","BK4195","BK4211","BK4124"],"gpt_icon":0},{"id":"2531305030","title":"Press Release: Lithium Royalty Corp. Announces First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531305030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531305030?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:16","pubTimestamp":1746018960,"startTime":"0","endTime":"0","summary":"-- LRC royalty revenue continues to outperform the broader lithium pricing. cycle, with approximately flat revenue year-over-year despite a 17%. -- Ganfeng Lithium inaugurated Mariana Lithium project in Salta, Argentina. during the quarter; first cash flow from the project anticipated in 2025. -- Multiple near-term catalysts across the portfolio: Zijin expects to start. production of Tres Quebradas in 3Q25 and Sigma estimates first production. LRC's ability to pursue high-quality royalty opportunities at attractive. Lithium Royalty Corp.   announces first quarter 2025 results. \"LRC's diversified business model with assets continuing to enter production and ramp up to nameplate is insulating us from the severe price declines in the sector. As the sector recalibrates, the portfolio is continuing to mature, setting up the company for success for the eventual lithium cycle recovery. The low-price environment for the sector has made acquisition opportunities more available and we are active","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","DFS","LU2360107671.USD","BK4211","BK4168","LU1791807156.HKD","BK4505","BK4166","BK4588","LU1861220207.SGD","BK4195","LU1861217088.USD","DMS","ROOT","LITRF","LU0106831901.USD","LU1668664300.SGD","FID","BK4009","BK4585","BK4107","PFS"],"gpt_icon":0},{"id":"2531303571","title":"BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2531303571","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531303571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study. Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits. Positive delayed-type hypersensitivity   and a favorable Neutrophil-to-Lymphocyte Ratio   linked to longer progression-free survival  in Phase 3 patients. Presence of Circulating Tumor Cells  after patients’ initial Phase 3 treatment supports role as negative prognostic marker . Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profile. “Using biomarkers as powerful instruments to predict patient responsiveness to the Bria-IMT treatment would allow physicians and oncologists to identify potential responders sooner, providing better clinical outcomes and ultimately extending patients’ lives,” stated Carmen Calfa, MD, Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-reports-breaker-phase-3-113000083.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4129","BK4097","BCTXW","CAML","DTH","NLR","BCTXZ","BK4606","PFS","BK4139","TPC","BK4195","BCTX","OS","BK4211"],"gpt_icon":0},{"id":"2531392850","title":"Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2531392850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531392850?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"Statistically significant efficacy in biomarker subgroup analyses was observed:. 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup. 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase  subgroup. 90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score  subgroup. The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study. Prolongation of 2.4 months in OS HR=0.81  and prolongation of 1.9 months in PFS HR=0.75  vs. control arm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/purple-biotech-reports-final-data-110000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4613","BK4552","ORR","BK4531","BK4195","BK4526","BK4108","BK4116","NET","01698","BK4535","IE00BYQNZ168.SGD","IE00B12V2V27.USD","IE00BYTNYN87.SGD","BK4548","SG9999011746.SGD","PFS","LU0359202008.SGD","BK4571","BK4565","CPS","BK4211","BK4588","BK4124","BK4560","BK4007","LU1023057109.AUD","PPBT","BK4554","OS","BK4097","BK4607","LU2039709279.SGD","LU2286300806.USD","LU0359201612.USD","BK4563","TME","BK4585","BK4509"],"gpt_icon":0},{"id":"2531765670","title":"GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765670","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765670?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:00","pubTimestamp":1745942400,"startTime":"0","endTime":"0","summary":"Advancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin's Potential in Solid Tumors. ATLANTA, GA - April 29, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin, at the American Association for Cancer Research  Annual Meeting 2025, being held April 2530 in Chicago, IL.The presentation, titled \"Viral-Vectored, Gene-Directed Prodrug Therapy  in Needle-Accessible Solid Tumors,\" was delivered by J. Marc Pipas, M.D., Executive Medical Director, Oncology at GeoVax, during the Phase II Clinical Trials 1 Poster Session on April 29, 2025. The session drew significant interest from researchers and clinicians, underscoring the growing recognition of Gedeptin's therapeutic potential. The corresponding abstract was published in the AACR journal Cancer Research.\"These clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-presents-gedeptin-r-clinical-160000847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4232","SD","BK4117","BK4588","BK4195","IT","LU2517655374.HKD","BK4134","OS","BK4107","LU1814569148.SGD","R","BK4097","LU0107464264.USD","LU2362541273.HKD","LU0154245673.USD","LU2517655291.USD","LU2517655028.SGD","PFS","BK4022","LU0154245756.USD","LU2362541513.USD","AFG","GOVX","GOVXW","BK4213","LU2362540622.SGD","BK4585","BK4139","BK4211","BK4583"],"gpt_icon":0},{"id":"2531759499","title":"Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759499","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759499?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:00","pubTimestamp":1745935200,"startTime":"0","endTime":"0","summary":"An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer  who received AFM24 at 480 mg weekly demonstrates that higher drug exposure  leads to improved objective response rate  and longer progression free survival   without a negative impact on safety. These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24. MANNHEIM, Germany, April 29, 2025  -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager  AFM24, in patients with advanced or metastatic non-small cell lung cancer  in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research .The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/affimed-shows-higher-exposure-afm24-140000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","AFMD","OS","BK4181","BK4195","ORR","PFS","PK","BK4097","BK4139","BK4218"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-07-24","symbol":"PFS","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/06","expectedEps":0.5,"defaultRemindTime":1753344000000,"name":null,"time":"Pre-Market","dateTimestamp":1753329600000,"actualEps":null},{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null},{"date":"2025-02-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-02-28"},{"market":"US","date":"2025-01-28","symbol":"PFS","fiscalQuarterEnding":"2024/12","expectedEps":0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-08-12","recordDate":"2015-08-14","paymentDate":"2015-08-28","value":0.16,"currency":"USD"},{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"},{"executeDate":"2016-08-11","recordDate":"2016-08-15","paymentDate":"2016-08-31","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1429,"buy":0.7143,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1750996800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-07-15","current":16.639161,"percent":0.789094,"low":6.410614,"twenty":8.954399,"median":10.697142,"eighty":16.928687,"high":33.979783,"avg":13.441578,"sd":6.423667,"marketCap":2453793710},"quantilePoints":[{"date":"2020-07-17","current":9.375082,"twenty":13.113766,"median":17.448564,"eighty":19.049774,"marketCap":906326643},{"date":"2020-07-24","current":9.601469,"twenty":13.098537,"median":17.431245,"eighty":19.049774,"marketCap":928212371},{"date":"2020-07-31","current":10.146984,"twenty":13.0648,"median":17.422118,"eighty":19.049774,"marketCap":878647633},{"date":"2020-08-07","current":10.689643,"twenty":13.048711,"median":17.403942,"eighty":19.049774,"marketCap":925637580},{"date":"2020-08-14","current":10.527035,"twenty":13.031177,"median":17.388517,"eighty":19.049774,"marketCap":911556975},{"date":"2020-08-21","current":9.599052,"twenty":13.008395,"median":17.362339,"eighty":19.049774,"marketCap":831201106},{"date":"2020-08-28","current":9.947973,"twenty":12.988694,"median":17.334295,"eighty":19.049774,"marketCap":861414913},{"date":"2020-09-04","current":10.155841,"twenty":12.944965,"median":17.31872,"eighty":19.049774,"marketCap":879414627},{"date":"2020-09-11","current":9.509966,"twenty":12.926046,"median":17.247931,"eighty":19.049774,"marketCap":823486942},{"date":"2020-09-18","current":9.539661,"twenty":12.903594,"median":17.204455,"eighty":19.049774,"marketCap":826058330},{"date":"2020-09-25","current":8.916057,"twenty":12.85637,"median":17.165483,"eighty":19.049774,"marketCap":772059186},{"date":"2020-10-02","current":9.457999,"twenty":12.836682,"median":17.1464,"eighty":19.049774,"marketCap":818987014},{"date":"2020-10-09","current":9.777225,"twenty":12.825762,"median":17.106994,"eighty":19.030829,"marketCap":846629433},{"date":"2020-10-16","current":9.658443,"twenty":12.807943,"median":17.057235,"eighty":18.996004,"marketCap":836343881},{"date":"2020-10-23","current":10.222656,"twenty":12.774984,"median":17.027417,"eighty":18.941136,"marketCap":885200250},{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":15.595237,"twenty":8.579877,"median":10.368229,"eighty":12.928956,"marketCap":1870555147},{"date":"2024-06-07","current":14.804645,"twenty":8.579877,"median":10.368229,"eighty":12.944965,"marketCap":1775728393},{"date":"2024-06-14","current":14.479745,"twenty":8.579877,"median":10.368229,"eighty":12.974084,"marketCap":1736758494},{"date":"2024-06-21","current":14.609705,"twenty":8.578848,"median":10.365511,"eighty":13.001042,"marketCap":1752346453},{"date":"2024-06-28","current":15.541087,"twenty":8.578848,"median":10.365511,"eighty":13.028149,"marketCap":1864060164},{"date":"2024-07-05","current":15.400297,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":1847173207},{"date":"2024-07-12","current":17.403852,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":2087487584},{"date":"2024-07-19","current":19.212466,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2304420021},{"date":"2024-07-26","current":32.346496,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2473083727},{"date":"2024-08-02","current":29.436843,"twenty":8.578848,"median":10.365511,"eighty":13.071794,"marketCap":2250623276},{"date":"2024-08-09","current":28.842709,"twenty":8.578848,"median":10.365511,"eighty":13.113823,"marketCap":2205198173},{"date":"2024-08-16","current":30.822445,"twenty":8.578848,"median":10.365511,"eighty":13.134508,"marketCap":2356560887},{"date":"2024-08-23","current":32.631515,"twenty":8.578848,"median":10.365511,"eighty":13.176313,"marketCap":2494875092},{"date":"2024-08-30","current":32.546181,"twenty":8.578848,"median":10.365511,"eighty":13.215944,"marketCap":2488350837},{"date":"2024-09-06","current":31.197913,"twenty":8.578848,"median":10.365511,"eighty":13.228055,"marketCap":2385267609},{"date":"2024-09-13","current":31.300313,"twenty":8.578848,"median":10.365511,"eighty":13.30073,"marketCap":2393096715},{"date":"2024-09-20","current":32.187781,"twenty":8.578848,"median":10.365511,"eighty":13.316627,"marketCap":2460948967},{"date":"2024-09-27","current":31.283246,"twenty":8.578848,"median":10.365511,"eighty":13.405115,"marketCap":2391791864},{"date":"2024-10-04","current":30.429912,"twenty":8.578848,"median":10.365511,"eighty":13.64376,"marketCap":2326549315},{"date":"2024-10-11","current":32.136581,"twenty":8.578848,"median":10.365511,"eighty":13.888037,"marketCap":2457034414},{"date":"2024-10-18","current":33.314182,"twenty":8.578848,"median":10.365511,"eighty":14.144229,"marketCap":2547069132},{"date":"2024-10-25","current":31.88058,"twenty":8.578848,"median":10.365511,"eighty":14.323115,"marketCap":2437461649},{"date":"2024-11-01","current":26.079311,"twenty":8.578848,"median":10.365511,"eighty":14.468915,"marketCap":2459644116},{"date":"2024-11-08","current":29.303632,"twenty":8.578848,"median":10.365511,"eighty":14.501405,"marketCap":2763742765},{"date":"2024-11-15","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.577215,"marketCap":2792450197},{"date":"2024-11-22","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.642195,"marketCap":2792450197},{"date":"2024-11-29","current":29.220619,"twenty":8.578848,"median":10.365511,"eighty":14.720538,"marketCap":2755913466},{"date":"2024-12-06","current":28.72254,"twenty":8.578848,"median":10.365511,"eighty":14.772155,"marketCap":2708937668},{"date":"2024-12-13","current":28.16912,"twenty":8.578848,"median":10.365511,"eighty":14.811522,"marketCap":2656742337},{"date":"2024-12-20","current":26.370502,"twenty":8.578848,"median":10.365511,"eighty":14.879507,"marketCap":2487107512},{"date":"2024-12-27","current":26.107627,"twenty":8.578848,"median":10.365511,"eighty":14.930682,"marketCap":2462314730},{"date":"2025-01-03","current":26.19064,"twenty":8.578848,"median":10.365511,"eighty":15.008136,"marketCap":2470144030},{"date":"2025-01-10","current":24.945443,"twenty":8.578722,"median":10.36461,"eighty":15.045075,"marketCap":2352704535},{"date":"2025-01-17","current":26.730225,"twenty":8.578722,"median":10.36461,"eighty":15.087294,"marketCap":2521034477},{"date":"2025-01-24","current":26.232147,"twenty":8.578722,"median":10.36461,"eighty":15.170193,"marketCap":2474058679},{"date":"2025-01-31","current":20.975271,"twenty":8.578722,"median":10.36461,"eighty":15.27162,"marketCap":2423168232},{"date":"2025-02-07","current":21.686872,"twenty":8.578722,"median":10.36461,"eighty":15.43113,"marketCap":2505375878},{"date":"2025-02-14","current":21.065633,"twenty":8.578722,"median":10.36461,"eighty":15.506431,"marketCap":2433607298},{"date":"2025-02-21","current":20.489576,"twenty":8.578722,"median":10.36461,"eighty":15.601522,"marketCap":2367058251},{"date":"2025-02-28","current":20.614008,"twenty":8.578722,"median":10.36461,"eighty":15.733365,"marketCap":2381433247},{"date":"2025-03-07","current":19.427996,"twenty":8.578596,"median":10.36371,"eighty":15.909803,"marketCap":2244419279},{"date":"2025-03-14","current":19.373214,"twenty":8.58723,"median":10.384564,"eighty":16.110435,"marketCap":2238090520},{"date":"2025-03-21","current":19.113398,"twenty":8.626133,"median":10.390798,"eighty":16.250162,"marketCap":2208075312},{"date":"2025-03-28","current":19.282843,"twenty":8.679674,"median":10.422436,"eighty":16.324736,"marketCap":2227650448},{"date":"2025-04-04","current":17.498022,"twenty":8.697705,"median":10.433885,"eighty":16.538637,"marketCap":2021459018},{"date":"2025-04-11","current":16.594315,"twenty":8.729831,"median":10.450581,"eighty":16.720339,"marketCap":1917058294},{"date":"2025-04-17","current":17.498022,"twenty":8.74788,"median":10.472646,"eighty":16.838352,"marketCap":2021459018},{"date":"2025-04-25","current":14.654875,"twenty":8.784492,"median":10.48224,"eighty":16.926427,"marketCap":2161169063},{"date":"2025-05-02","current":15.142189,"twenty":8.798752,"median":10.513034,"eighty":16.926427,"marketCap":2233033814},{"date":"2025-05-09","current":15.159534,"twenty":8.804878,"median":10.526765,"eighty":16.926427,"marketCap":2235591607},{"date":"2025-05-16","current":15.505075,"twenty":8.82909,"median":10.533858,"eighty":16.926427,"marketCap":2286548985},{"date":"2025-05-23","current":14.787412,"twenty":8.855843,"median":10.556785,"eighty":16.926427,"marketCap":2180714431},{"date":"2025-05-30","current":14.884872,"twenty":8.8606,"median":10.572534,"eighty":16.926427,"marketCap":2195087025},{"date":"2025-06-06","current":14.619071,"twenty":8.875633,"median":10.60779,"eighty":16.926427,"marketCap":2155889043},{"date":"2025-06-13","current":15.000053,"twenty":8.887975,"median":10.619572,"eighty":16.926427,"marketCap":2212072818},{"date":"2025-06-20","current":14.30011,"twenty":8.911603,"median":10.626285,"eighty":16.928687,"marketCap":2108851463},{"date":"2025-06-27","current":15.850617,"twenty":8.946056,"median":10.641658,"eighty":16.928687,"marketCap":2337506362},{"date":"2025-07-03","current":16.710041,"twenty":8.946056,"median":10.65175,"eighty":16.928687,"marketCap":2464246506},{"date":"2025-07-11","current":16.648021,"twenty":8.954399,"median":10.683931,"eighty":16.928687,"marketCap":2455100310},{"date":"2025-07-15","current":16.639161,"twenty":8.954399,"median":10.697142,"eighty":16.928687,"marketCap":2453793710}],"updateTime":1752662867522}}}